In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.
For more than a decade, ticagrelor (Brilinta in the US and Brilique in Europe) has been recommended for patients with acute coronary syndrome — a range of conditions related to sudden reduced blood flow to the heart.
Last December, an investigation by The BMJ found serious data integrity problems in the landmark clinical…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply